Buy DUROLANE®
Showing the single result
-


DUROLANE®
$ 259.00 Add To Cart-+Orthopedic specialists, sports medicine physicians, rheumatologists, and medical buyers looking to buy DUROLANE® can source this single-injection NASHA® hyaluronic acid viscosupplement through Direct Doctor Supply. Supplied as a 60 mg/3 mL prefilled syringe, DUROLANE® is indicated for the symptomatic relief of pain associated with knee osteoarthritis in adults who have not achieved adequate relief from conservative management. Its stabilized hyaluronic acid formulation is designed to replenish synovial fluid that assists in lubrication and cushioning within the affected joint. Since 2014, Direct Doctor Supply has been a trusted wholesale supplier for licensed healthcare professionals worldwide. Browse the catalogue below to compare DUROLANE® injection options and find reliable wholesale solutions.
Who Is DUROLANE® For? — Knee Osteoarthritis Indications and Patient Profile
DUROLANE® is indicated in the United States for the treatment of pain associated with osteoarthritis of the knee in adults who have not achieved adequate symptom relief from conservative therapies, including exercise, weight management, physical therapy, and simple analgesics such as acetaminophen.[1][2]
Candidates typically suited to DUROLANE® knee injections include adults with confirmed knee OA who continue to experience pain and functional limitation despite conservative care, who prefer a single-visit treatment over multi-injection regimens, or who are seeking to delay surgical intervention while managing symptoms more effectively.[1] Clinicians should evaluate each patient’s disease severity, joint status, activity demands, and overall treatment goals before recommending viscosupplementation therapy.
DUROLANE® is contraindicated in patients with active joint infection or skin disease at the intended injection site, and in those with known hypersensitivity to sodium hyaluronate preparations. Safety has not been established in children or during pregnancy and lactation. Clinicians should always consult the current Instructions for Use before administration.[2]
How DUROLANE® Works — NASHA® Technology
DUROLANE® is a gel preparation composed of highly purified sodium hyaluronate produced through bacterial biofermentation. After intra-articular administration, it supplements the synovial fluid within the joint, helping to restore the viscoelastic properties responsible for lubrication, cushioning, and shock absorption.[2][4]
In osteoarthritic knees, both the concentration and molecular weight of endogenous hyaluronic acid decline as the condition progresses, reducing the joint’s ability to absorb mechanical stress and contributing to chronic knee pain, stiffness, and reduced mobility. DUROLANE® replenishes joint fluid and helps restore normal joint mechanics through its stabilized hyaluronic acid formulation.[2][4]
Its proprietary NASHA® (Non-Animal Stabilized Hyaluronic Acid) technology applies minimal cross-linking to slow enzymatic degradation within the joint space. This extended residence time allows a single injection to remain active substantially longer than non-cross-linked formulations, supporting prolonged symptomatic relief from a single treatment session.[3][4]
DUROLANE® is not a corticosteroid. It is a hyaluronic acid medical device that works by restoring the viscoelastic characteristics of synovial fluid rather than suppressing inflammation through steroid activity. Because it is produced through bacterial biofermentation, DUROLANE® contains no avian-derived proteins — a formulation characteristic that clinicians may consider when reviewing individual patient histories alongside the current IFU.[2]
About DUROLANE® — A Single-Injection NASHA® Viscosupplement
DUROLANE® is a sterile NASHA® hyaluronic acid gel supplied as a single prefilled syringe containing 60 mg of sodium hyaluronate in 3 mL (20 mg/mL) for intra-articular administration. The product received U.S. FDA Premarket Approval (PMA P170007) in 2017 for the treatment of knee osteoarthritis pain in eligible adult patients who have failed conservative therapy.[1]
As a single-SKU brand, DUROLANE® simplifies procurement and inventory management for orthopedic, sports medicine, and rheumatology practices. Clinics stock one presentation only, making ordering straightforward while offering a single-injection viscosupplement with a well-established clinical record spanning more than two decades of international use.[1][4]
About the Manufacturer
DUROLANE® is legally manufactured by Q-Med AB, a Swedish medical device company with deep expertise in hyaluronic acid technology and stabilized gel formulations. DUROLANE® is distributed in the United States by Bioventus LLC, a company focused on orthobiologic therapies that support musculoskeletal health, with a portfolio spanning joint preservation, bone healing, and restorative orthopedic care.[2]
DUROLANE® has accumulated more than two decades of international clinical experience and remains one of the flagship NASHA® hyaluronic acid viscosupplements in the orthopedic market. In the pivotal randomized controlled trial evaluated for FDA approval, a single injection of DUROLANE® demonstrated pain reduction that was non-inferior to a multi-injection HA regimen throughout the 26-week study period.[3] Published systematic reviews have continued to support its safety and effectiveness profile in appropriately selected patients with knee osteoarthritis.[4]
DUROLANE® Product Spotlight
DUROLANE® (Sodium Hyaluronate, 60 mg/3 mL — Single Injection) is a ready-to-use sterile prefilled syringe, formulated for a single intra-articular injection into the knee joint.[2] It is manufactured through bacterial biofermentation, making it a non-animal-derived hyaluronic acid product. This standardized single-SKU presentation eliminates dose preparation, supporting workflow efficiency and dosing consistency across clinical settings.
According to the current Instructions for Use, DUROLANE® should be stored in its original packaging at 0°C to 30°C (32°F–86°F). Refrigeration is not required, but the product must be protected from freezing and excessive heat. Healthcare professionals should always verify storage requirements against the most current manufacturer labeling before use.[2]
Regarding the DUROLANE® NDC number: NDC codes may differ depending on packaging configuration, distributor, and product updates. Practices should verify the current NDC directly from the manufacturer’s labeling or distribution documentation before billing or inventory reconciliation.
Why Practitioners Choose DUROLANE®
The NASHA® cross-linking technology supports an extended joint residence time compared with non-cross-linked hyaluronic acid preparations, enabling a single injection to deliver symptomatic relief that was demonstrated throughout a 26-week pivotal RCT.[3][4] This reduces the visit frequency burden associated with multi-injection regimens for both practitioners and patients without requiring a change in active substance across the treatment course.
DUROLANE® also simplifies formulary management. Practices stock one presentation to cover their knee OA viscosupplementation needs, reducing inventory complexity and streamlining the procurement process — an operational benefit for busy orthopedic, sports medicine, and rheumatology clinics alike.
Practices looking to expand their musculoskeletal offerings can buy orthopedic injections across multiple brands through the Direct Doctor Supply catalogue.
Administration and Recovery
DUROLANE® should be administered only by trained healthcare professionals using strict aseptic technique. The product is injected directly into the synovial cavity of the knee joint following appropriate patient assessment. When clinically indicated, excess synovial fluid should be aspirated before injection using standard procedural technique. Image guidance, such as ultrasound, may be used to help direct the needle into the joint space when appropriate.[2]
Some patients report initial improvement within several days of treatment, while others experience gradual symptom relief over subsequent weeks. In the pivotal randomized controlled trial, pain reduction with a single DUROLANE® injection was non-inferior to a multi-injection HA comparator throughout the 26-week study period, though individual responses vary according to disease severity and patient-specific factors.[3]
Following injection, patients are advised to avoid strenuous or prolonged weight-bearing activities — including running, tennis, or heavy lifting — for 48 hours post-injection to allow the joint to settle, per the manufacturer’s precautions.[2] Mild discomfort, swelling, or warmth at the injection site is possible and typically resolves within several days. Patients should contact their clinician if pain, swelling, or other symptoms persist or worsen beyond the expected recovery window.
Regulatory Status and Billing
DUROLANE® received U.S. FDA Premarket Approval (PMA P170007) in 2017 for the treatment of pain associated with knee osteoarthritis in adults who have not achieved adequate relief with conservative therapy. FDA approval followed review of clinical evidence, including the pivotal CHASE study, supporting the device’s safety and effectiveness for its labeled indication.[1][3]
DUROLANE® J Code
For reimbursement, DUROLANE® is billed using HCPCS code J7318, which covers hyaluronan or derivative for intra-articular injection, billed per 1 mg. A standard 60 mg syringe is typically reported as 60 billing units. Providers should verify payer-specific billing requirements and current coding guidance before claim submission.[5]
DUROLANE® CPT Code
The large-joint injection procedure itself is commonly reported using CPT 20610 (major joint injection without imaging guidance) or CPT 20611 (major joint injection with ultrasound guidance and permanent image documentation). Appropriate code selection depends on the procedure performed and applicable payer policies, and should be confirmed against current coding guidance before billing.[5]
Medicare Part B may cover DUROLANE® where local coverage determination (LCD) criteria are met, including documented symptomatic knee osteoarthritis and inadequate response to conservative management consistent with FDA-approved labeling. Coverage policies, documentation requirements, and patient cost-sharing can vary by Medicare Administrative Contractor (MAC) or Medicare Advantage plan, so eligibility should always be confirmed before treatment.[5]
Distribution and Market Availability
DUROLANE® is available through authorized distributors in the United States and numerous international markets. Licensed healthcare professionals looking to order DUROLANE® online or purchase DUROLANE® for their practice can access the Direct Doctor Supply catalogue, request bulk pricing, and receive dedicated procurement support throughout the ordering process.
Since 2014, Direct Doctor Supply has supplied licensed practitioners worldwide with authentic orthopedic products supported by competitive wholesale pricing and dependable international delivery. Practices that also buy HA dermal fillers can manage both orthopedic and aesthetic procurement through a single trusted platform.
DUROLANE® Safety Profile
DUROLANE® has an established safety profile supported by clinical studies and post-market experience. The most frequently reported side effects of DUROLANE® injections are local and transient, typically resolving within several days without additional intervention:[2][4]
- Injection-site pain
- Localized swelling
- Stiffness
- Warmth
- Mild joint discomfort
As with any intra-articular procedure, risks associated with DUROLANE® injections include infection, transient inflammatory reactions, and hypersensitivity responses. Appropriate aseptic technique and careful patient selection remain essential for minimizing complications.[2][4]
DUROLANE® should not be administered to patients with active joint infection, skin infection or disease at the intended injection site, or known hypersensitivity to sodium hyaluronate preparations. Safety has not been established during pregnancy, breastfeeding, or in pediatric patients. Healthcare professionals should review the complete Instructions for Use before treatment.[2]
DUROLANE® vs Competing Viscosupplements
Several hyaluronic acid viscosupplements are available for managing knee osteoarthritis-related joint pain. While they share the same therapeutic goal, they differ in formulation technology, injection schedule, source material, and approved indications.
DUROLANE® vs MONOVISC®
Both DUROLANE® and MONOVISC® are non-animal single-injection viscosupplements for knee osteoarthritis, yet they differ in cross-linking technology and proprietary formulation approach.[2][4] Clinicians comparing the two typically evaluate NASHA® stabilization alongside patient-specific factors and local availability. Practices that carry both can buy MONOVISC® through Direct Doctor Supply to offer patients a choice between single-injection options.
DUROLANE® vs SYNVISC®
SYNVISC-ONE® contains avian-derived hylan G-F 20, while DUROLANE® uses NASHA® non-animal sodium hyaluronate produced through bacterial biofermentation — a formulation distinction clinicians may weigh when reviewing individual patient profiles and the applicable IFU.[2][4] Practices that stock both single-injection products can buy SYNVISC® on Direct Doctor Supply alongside DUROLANE®.
DUROLANE® vs ORTHOVISC®
A key practical difference between these two products is treatment schedule: ORTHOVISC® requires three or four weekly injections, while DUROLANE® delivers the complete course in a single visit.[1][2] For clinics that prefer to buy ORTHOVISC® as a multi-injection alternative, Direct Doctor Supply carries both, allowing practices to match protocol to patient preference without switching suppliers.
DUROLANE® vs EUFLEXXA®
Both DUROLANE® and EUFLEXXA® use non-animal, bioengineered hyaluronic acid, but differ in dosing: EUFLEXXA® is administered as a three-injection series, whereas DUROLANE® completes treatment in a single session.[2][4] Clinics looking to buy EUFLEXXA® for patients who benefit from a staged protocol can source it through the same Direct Doctor Supply platform.
DUROLANE® vs HYALGAN®
Formulation source and visit frequency set these two products apart — HYALGAN® is an avian-derived product delivered across multiple appointments, while DUROLANE® uses stabilized non-animal hyaluronic acid in a single injection.[2] Practices that want to buy HYALGAN® alongside DUROLANE® can source both through Direct Doctor Supply, maintaining avian-derived and non-animal viscosupplement options within a single formulary.
DUROLANE® vs SUPARTZ®
SUPARTZ FX® is an avian-derived viscosupplement typically administered over three to five injections, whereas DUROLANE® provides a complete course in a single procedure using non-animal NASHA® hyaluronic acid.[2][4] Orthopedic practices that want to buy SUPARTZ® as a multi-injection complement to DUROLANE® can order both through Direct Doctor Supply.
Direct Doctor Supply has supplied professional-grade orthopedic and aesthetic injectable products to licensed healthcare professionals since 2014, offering wholesale deals, guaranteed delivery, and a dedicated support team for sourcing and documentation assistance. Practitioners looking to buy DUROLANE® online or buy DUROLANE® wholesale can contact the Direct Doctor Supply support team for product availability and pricing guidance. Those seeking to purchase DUROLANE® in volume can also ask about recurring wholesale arrangements and consolidated ordering. Practices with broader treatment portfolios can buy dermal fillers through the same platform, covering both orthopedic and aesthetic procurement needs from a single supplier.
Frequently Asked Questions
What is DUROLANE®?
DUROLANE® is a single-injection NASHA® hyaluronic acid viscosupplement supplied as a 60 mg/3 mL prefilled syringe, indicated for the treatment of pain associated with knee osteoarthritis in adults who have not achieved adequate relief from conservative management.[1][2]
How does DUROLANE® work?
DUROLANE® replenishes synovial fluid and helps restore the viscoelastic properties of the knee joint through its NASHA®-stabilized hyaluronic acid formulation. The minimal cross-linking slows enzymatic degradation within the joint space, supporting extended symptomatic relief from a single administration.[2][4]
Is DUROLANE® a steroid?
No. DUROLANE® is a hyaluronic acid medical device and contains no corticosteroids. It works by supplementing and restoring synovial fluid viscoelasticity rather than suppressing inflammation through steroid activity.[2]
How long does it take for a DUROLANE® injection to work?
Some patients report initial improvement within several days of treatment, while symptom relief may continue to develop over subsequent weeks. In the pivotal 26-week RCT, DUROLANE® demonstrated pain reduction non-inferior to a multi-injection HA comparator, though individual outcomes vary by disease severity and patient characteristics.[3]
Can you walk after a DUROLANE® injection?
Patients are advised to avoid strenuous or prolonged weight-bearing activities for 48 hours following injection to allow the joint to settle, per the manufacturer’s precautions.[2] Specific activity guidance should always follow the treating clinician’s recommendation and the current product IFU.
Does DUROLANE® need to be refrigerated?
Refrigeration is not required. DUROLANE® should be stored between 0°C and 30°C (32°F–86°F) in its original packaging and protected from freezing. Healthcare professionals should always confirm storage requirements against the current manufacturer Instructions for Use.[2]
What are the DUROLANE® HCPCS and CPT billing codes?
DUROLANE® is commonly billed using HCPCS code J7318 for the hyaluronan supply component, and CPT 20610 or CPT 20611 for the large-joint injection procedure, depending on whether imaging guidance is used. Providers should verify applicable codes and payer requirements before claim submission.[5]
What is the success rate of DUROLANE® injections?
In the pivotal randomized controlled trial, a single DUROLANE® injection demonstrated pain reduction non-inferior to a multi-injection HA regimen over 26 weeks. Published systematic reviews further support its safety and effectiveness in appropriately selected knee OA patients, though individual outcomes vary by disease severity and patient-specific factors.[3][4]
Looking to buy DUROLANE® Products?
The Direct Doctor Supply catalogue gives licensed practitioners direct access to DUROLANE® with dependable stock, wholesale pricing, and worldwide delivery — backed by a support team that has served verified medical practices since 2014. The support staff can assist with sourcing inquiries, DUROLANE® NDC number references, and documentation support for new and recurring orders.
Citations and Resources about DUROLANE®
[1] U.S. Food and Drug Administration. DUROLANE Premarket Approval (P170007). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170007
[2] U.S. Food and Drug Administration. DUROLANE® INSTRUCTIONS FOR USE. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170007D.pdf
[3] Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Research & Therapy. 2015. https://pubmed.ncbi.nlm.nih.gov/25889322/
[4] Leighton R, Fitzpatrick J, Smith H, Crandall D, Flannery CR, Conrozier T. Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis. Open Access Rheumatology Research & Reviews. 2018. https://pubmed.ncbi.nlm.nih.gov/29849470/
[5] Centers for Medicare & Medicaid Services. Local Coverage Determination: Hyaluronic acid injections for knee osteoarthritis (LCD L39260). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39260
All content on this website is intended for informational purposes and does not constitute medical advice.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.
